Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Sela

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Journal of Neuroimmunology|June 8, 2006
Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cellsBadiga Venkata Aruna, Michael Sela, Edna Mozes
International Immunopharmacology|December 14, 2004
Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejectionRina Aharoni, Alexander Yussim, Michael Sela, et al.
Journal of Neuroimmunology|May 22, 2002
Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous systemRina Aharoni, Asher Meshorer, Michael Sela, et al.
British Journal of Pharmacology|February 3, 2016
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, et al.
Molecular Oncology|April 23, 2009
Cancer therapeutic antibodies come of age: targeting minimal residual diseaseTsipi Ben-Kasus, Bilha Schechter, Michael Sela, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2003
Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situRina Aharoni, Basak Kayhan, Raya Eilam, et al.
Immunology|July 11, 2006
A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosisBadiga Venkata Aruna, Hava Ben-David, Michael Sela, et al.
Biochemical and Biophysical Research Communications|August 7, 2015
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor bindingGeorg Mahlknecht, Ruth Maron, Bilha Schechter, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 25, 2007
The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligandHava Ben-David, Amir Sharabi, Molly Dayan, et al.
Infection and Immunity|July 15, 2009
Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath componentsGabriel Nussbaum, Shimon Ben-Adi, Tamar Genzler, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Journal of Neuroimmunology|June 8, 2006
Down-regulation of T cell responses to AChR and reversal of EAMG manifestations in mice by a dual altered peptide ligand via induction of CD4+ CD25+ regulatory cellsBadiga Venkata Aruna, Michael Sela, Edna Mozes
International Immunopharmacology|December 14, 2004
Combined treatment of glatiramer acetate and low doses of immunosuppressive drugs is effective in the prevention of graft rejectionRina Aharoni, Alexander Yussim, Michael Sela, et al.
Journal of Neuroimmunology|May 22, 2002
Oral treatment of mice with copolymer 1 (glatiramer acetate) results in the accumulation of specific Th2 cells in the central nervous systemRina Aharoni, Asher Meshorer, Michael Sela, et al.
British Journal of Pharmacology|February 3, 2016
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, et al.
Molecular Oncology|April 23, 2009
Cancer therapeutic antibodies come of age: targeting minimal residual diseaseTsipi Ben-Kasus, Bilha Schechter, Michael Sela, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 14, 2003
Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situRina Aharoni, Basak Kayhan, Raya Eilam, et al.
Immunology|July 11, 2006
A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosisBadiga Venkata Aruna, Hava Ben-David, Michael Sela, et al.
Biochemical and Biophysical Research Communications|August 7, 2015
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor bindingGeorg Mahlknecht, Ruth Maron, Bilha Schechter, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 25, 2007
The role of CD8+CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligandHava Ben-David, Amir Sharabi, Molly Dayan, et al.
Infection and Immunity|July 15, 2009
Involvement of Toll-like receptors 2 and 4 in the innate immune response to Treponema denticola and its outer sheath componentsGabriel Nussbaum, Shimon Ben-Adi, Tamar Genzler, et al.
Pageof 5